SG11201803153RA - Oxadiazaspiro compounds for the treatment of drug abuse and addiction - Google Patents
Oxadiazaspiro compounds for the treatment of drug abuse and addictionInfo
- Publication number
- SG11201803153RA SG11201803153RA SG11201803153RA SG11201803153RA SG11201803153RA SG 11201803153R A SG11201803153R A SG 11201803153RA SG 11201803153R A SG11201803153R A SG 11201803153RA SG 11201803153R A SG11201803153R A SG 11201803153RA SG 11201803153R A SG11201803153R A SG 11201803153RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compounds
- barcelona
- addiction
- drug abuse
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382566 | 2015-11-16 | ||
| PCT/EP2016/001907 WO2017084752A1 (en) | 2015-11-16 | 2016-11-15 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803153RA true SG11201803153RA (en) | 2018-06-28 |
Family
ID=54707728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803153RA SG11201803153RA (en) | 2015-11-16 | 2016-11-15 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10927128B2 (ja) |
| EP (1) | EP3377500B1 (ja) |
| JP (1) | JP6884974B2 (ja) |
| KR (1) | KR20180080327A (ja) |
| CN (1) | CN108349999A (ja) |
| AR (1) | AR106697A1 (ja) |
| AU (1) | AU2016356488B2 (ja) |
| CA (1) | CA3002286A1 (ja) |
| CO (1) | CO2018004665A2 (ja) |
| DK (1) | DK3377500T3 (ja) |
| ES (1) | ES2932000T3 (ja) |
| HR (1) | HRP20221343T1 (ja) |
| HU (1) | HUE060275T2 (ja) |
| IL (1) | IL259035B (ja) |
| LT (1) | LT3377500T (ja) |
| MA (1) | MA43250B1 (ja) |
| MX (1) | MX2018005439A (ja) |
| MY (1) | MY193423A (ja) |
| PH (1) | PH12018500814A1 (ja) |
| PL (1) | PL3377500T3 (ja) |
| PT (1) | PT3377500T (ja) |
| RS (1) | RS63734B1 (ja) |
| SG (1) | SG11201803153RA (ja) |
| SI (1) | SI3377500T1 (ja) |
| TN (1) | TN2018000122A1 (ja) |
| TW (1) | TWI756196B (ja) |
| UA (1) | UA123775C2 (ja) |
| WO (1) | WO2017084752A1 (ja) |
| ZA (1) | ZA201802845B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA123775C2 (uk) | 2015-11-16 | 2021-06-02 | Естев Фармас'Ютікалз, С.А. | Оксадіазаспіросполуки для лікування зловживання наркотичними засобами та залежності від них |
| WO2020157026A1 (en) * | 2019-01-28 | 2020-08-06 | Esteve Pharmaceuticals, S.A. | Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
| CA3230908A1 (en) | 2021-09-20 | 2023-03-23 | Jose-Miguel Vela-Hernandez | Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4244961A (en) * | 1978-10-26 | 1981-01-13 | Syntex (U.S.A.) Inc. | 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents |
| US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
| WO2005075484A2 (en) * | 2004-02-10 | 2005-08-18 | F. Hoffmann-La Roche Ag | Chemokine ccr5 receptor modulators |
| WO2005084678A1 (en) | 2004-03-03 | 2005-09-15 | Vital Health Sciences Pty Ltd | Alkaloid formulations |
| EP1790639B1 (en) * | 2004-08-27 | 2014-03-26 | Ono Pharmaceutical Co., Ltd. | Spirocyclic compounds and their use as cxcr4-antagonists |
| EP1634873A1 (en) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| CN101228127B (zh) * | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | 哌啶衍生物 |
| CN101203567A (zh) * | 2005-06-07 | 2008-06-18 | 西巴特殊化学品控股有限公司 | 抗刮擦聚烯烃 |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| BRPI0618417A2 (pt) | 2005-10-19 | 2012-07-31 | Gruenenthal Chemie | novos ligandos de receptores de vanilàide e seu uso para produzir medicamentos |
| JP5217438B2 (ja) | 2005-11-18 | 2013-06-19 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
| EP1829869A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands |
| EP1847542A1 (en) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor |
| EP2128154B1 (en) | 2007-03-01 | 2015-04-08 | Mitsubishi Tanabe Pharma Corporation | Benzimidazole compound and pharmaceutical use thereof |
| EP1982714A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| US20110190280A1 (en) | 2007-08-29 | 2011-08-04 | George Adjabeng | Thiazole And Oxazole Kinase Inhibitors |
| EP2070933A1 (en) | 2007-12-07 | 2009-06-17 | Laboratorios del Dr. Esteve S.A. | Tricyclic triazolic compounds |
| CN102083839B (zh) | 2008-02-06 | 2014-03-26 | 阿斯利康(瑞典)有限公司 | 化合物 |
| EP2108643A1 (en) * | 2008-04-10 | 2009-10-14 | Laboratorios Del. Dr. Esteve, S.A. | 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist |
| GB201016912D0 (en) * | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| WO2013052716A1 (en) * | 2011-10-07 | 2013-04-11 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| WO2013115294A1 (ja) * | 2012-01-31 | 2013-08-08 | 東レ株式会社 | ジアザスピロウレア誘導体及びその医薬用途 |
| WO2015017305A1 (en) | 2013-07-31 | 2015-02-05 | Merck Sharp & Dohme Corp | Inhibitors of the renal outer medullary potassium channel |
| TWI685497B (zh) * | 2014-06-02 | 2020-02-21 | 西班牙商伊史帝夫製藥公司 | 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物 |
| TW201615642A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物 |
| TW201615643A (zh) * | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物 |
| WO2016122994A1 (en) | 2015-01-29 | 2016-08-04 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| UA123775C2 (uk) | 2015-11-16 | 2021-06-02 | Естев Фармас'Ютікалз, С.А. | Оксадіазаспіросполуки для лікування зловживання наркотичними засобами та залежності від них |
-
2016
- 2016-11-15 UA UAA201806353A patent/UA123775C2/uk unknown
- 2016-11-15 TW TW105137236A patent/TWI756196B/zh active
- 2016-11-15 LT LTEPPCT/EP2016/001907T patent/LT3377500T/lt unknown
- 2016-11-15 RS RS20221052A patent/RS63734B1/sr unknown
- 2016-11-15 AR ARP160103486A patent/AR106697A1/es unknown
- 2016-11-15 HU HUE16797458A patent/HUE060275T2/hu unknown
- 2016-11-15 DK DK16797458.3T patent/DK3377500T3/da active
- 2016-11-15 TN TNP/2018/000122A patent/TN2018000122A1/en unknown
- 2016-11-15 JP JP2018524257A patent/JP6884974B2/ja active Active
- 2016-11-15 ES ES16797458T patent/ES2932000T3/es active Active
- 2016-11-15 PL PL16797458.3T patent/PL3377500T3/pl unknown
- 2016-11-15 SG SG11201803153RA patent/SG11201803153RA/en unknown
- 2016-11-15 PT PT167974583T patent/PT3377500T/pt unknown
- 2016-11-15 CN CN201680066748.9A patent/CN108349999A/zh active Pending
- 2016-11-15 MY MYPI2018701503A patent/MY193423A/en unknown
- 2016-11-15 US US15/774,407 patent/US10927128B2/en active Active
- 2016-11-15 EP EP16797458.3A patent/EP3377500B1/en active Active
- 2016-11-15 CA CA3002286A patent/CA3002286A1/en active Pending
- 2016-11-15 AU AU2016356488A patent/AU2016356488B2/en active Active
- 2016-11-15 SI SI201631621T patent/SI3377500T1/sl unknown
- 2016-11-15 MA MA43250A patent/MA43250B1/fr unknown
- 2016-11-15 HR HRP20221343TT patent/HRP20221343T1/hr unknown
- 2016-11-15 MX MX2018005439A patent/MX2018005439A/es unknown
- 2016-11-15 WO PCT/EP2016/001907 patent/WO2017084752A1/en active Application Filing
- 2016-11-15 KR KR1020187017092A patent/KR20180080327A/ko not_active Application Discontinuation
-
2018
- 2018-04-16 PH PH12018500814A patent/PH12018500814A1/en unknown
- 2018-04-30 ZA ZA2018/02845A patent/ZA201802845B/en unknown
- 2018-04-30 CO CONC2018/0004665A patent/CO2018004665A2/es unknown
- 2018-04-30 IL IL259035A patent/IL259035B/en active IP Right Grant
-
2020
- 2020-12-21 US US17/128,738 patent/US11649248B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807778YA (en) | Bicyclic compounds for diagnosis and therapy | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201809799WA (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201906543RA (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201803153RA (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201809086YA (en) | Treatment of liver, biliary tract and pancreatic disorders |